LOUISVILLE, Ky. (WDRB) -- Some COVID-19 patients will be able to receive an antibody infusion treatment from U of L Health that is designed to help the body fight off the virus.
U of L Health will begin administering the treatment beginning Thursday. The monoclonal antibody, "Bamlanivimab," is a single-dose infusion targeted toward early disease treatment in select high-risk patients.
“It is something that we can offer patients to hopefully keep them out of the hospital during this time where we’ve got a surge of patients being in into our current healthcare system,” U of L Health Dr. Jason Smith said.
The treatment is for COVID-19 positive patients over the age of 12, weighing more than 88 pounds and who are at risk for severe COVID-19 and possible hospitalization.
“It keeps you from having a lot of the severe symptoms associated with it by providing you an artificial immunity so to speak,” Smith said.
According to the FDA, Bamlanivimab was shown in clinical trials to reduce COVID-19-related hospitalization or emergency room visits in patients at high risk for disease progression within 28 days after treatment.
“Anything we can do right now to disrupt this cycle, or anything we can do to keep people from having to come to the hospital, is going to help our health care system overall and allow us to remain open so we can care for those who are most severely impacted by the disease,” Smith said.
U of L Health, Mary and Elizabeth Hospital and U of L Health and Medical Center East are the initial locations where the treatment will be administered. U of L Health said it is considering other locations.
“I anticipate having more of this drug available as it goes through more production cycles, but for now, we will take what we can get to try and stem this tide of COVID-positive patients,” Smith said.
The treatment requires a physician's order. Those wishing to receive the treatment should consult their physician.
U of L Health has 100 doses of the antibody infusion.
Copyright 2020 WDRB Media. All Rights Reserved.